

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on August 25, 2003

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

1648
#12
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1648
Patent Application
Docket No. EPI-T101D4
Serial No. 09/863,054

RECEIVED
AUG 28 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Donna C. Wortman
Art Unit : 1648
Applicant : Francis V. Chisari
Serial No. : 09/863,054
Filed : May 21, 2001
For : Peptides for Inducing Cytotoxic T Lymphocyte Responses to Hepatitis B Virus

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,

Glenn P. Ladwig
Glenn P. Ladwig
Patent Attorney

Registration No. 46,853
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

GPL/mv

Attachments: Form PTO/SB/08 (2 page); copies of references cited therein.



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Applicant Number 09/863,054
Filing Date May 21, 2001
First Named Inventor Francis V. Chisari
Group Art Unit 1648
Examiner Name Donna C. Wortman
Attorney Docket Number EPI-T101D4

RECEIVED
AUG 28 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1	5,780,036		Chisari	07-14-1998	All
	U2	6,322,789	B1	Vitiello et al.	11-27-2001	All
	U3					
	U4					
	U5					
	U6					
	U7					
	U8					
	U9					
	U10					
	U11					
	U12					
	U13					
	U14					
	U15					
	U16					
	U17					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	F1	WO	94/20127	A1	Cytel Corp.	09-15-1994	All	
	F2	WO	94/25060	A1	Ladd et al.	11-10-1994	All	
	F3	WO	95/04817	A1	Cytel Corp.	02-16-1995	All	
	F4	WO	92/00753	A1	Regents of Univ. of Calif.	01-23-1992	All	
	F5	WO	94/03205	A1	Cytel Corp.	02-17-1994		
	F6	EP	327369	A2	Regents of Univ. of Calif.	08-09-1989	All	
	F7							
	F8							


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



AUG 27 2003

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/863,054
Filing Date	May 21, 2001
First Named Inventor	Francis V. Chisan
Group Art Unit	1648
Examiner Name	Donna C. Wortman
Attorney Docket Number	EPI-T101D4

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	R1	CARBONE, F.R. and M.J. BEVAN "Induction of Ovalbumin-Specific Cytotoxic T Cells by In Vivo Peptide Immunization" <i>J. Exp. Med.</i> , March 1989, 169:603-612.
	R2	COLLINS, D.S. <i>et al.</i> "Processing of Exogenous Liposome-Encapsulated Antigens In Vivo Generates Class I MHC-Restricted T Cell Response" <i>J. Immunology</i> , 1992, 148:3336-3341.
	R3	LEE, K.K. <i>et al.</i> "Cross-Reactive and Strain-Specific Antipeptide Antibodies to <i>Pseudomonas aeruginosa</i> PAK and PAO Pil" <i>Infection and Immunity</i> , September 1990, 58(9):2727-2732.
	R4	MACK, D.H. <i>et al.</i> "Hepatitis B Virus Particles Contain a Polypeptide Encoded by the Largest Open Reading Frame: A Putative Reverse Transcriptase" <i>J. Virology</i> , December 1988, 62(12):4786-4790.
	R5	PASEK, M. <i>et al.</i> "Hepatitis B virus genes and their expression in <i>E. coli</i> " <i>Nature</i> , December 6, 1979, 282:575-579.
	R6	REDDY, R. <i>et al.</i> "In Vivo Cytotoxic T Lymphocyte Induction with Soluble Proteins Administered in Liposomes" <i>J. Immunology</i> , March 1, 1992, 148(5):1585-1589.
	R7	YSSEL, H. <i>et al.</i> "T Cell Activation-Inducing Epitopes of the House Dust Mite Allergen <i>Der p 1</i> " <i>J. Immunology</i> , February 1, 1992, 148(3):738-745.
	R8	
	R9	
	R10	
	R11	
	R12	
	R13	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.